SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
ARWR reported 2026 fiscal year ended September 30, 2026 results. The stock moved +1.3% on the print.
ARWRearnings

Earnings reactions, page 3

Arrowhead Pharmaceuticals, Inc. (ARWR) FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Net loss attributable to Arrowhead Pharmaceuticals, Inc. was $724,206 thousand for the year ended September 30, 2026.
  • Revenue was $450,817 thousand for the year ended September 30, 2026.
  • Total operating expenses were $1,157,988 thousand for the year ended September 30, 2026.
  • Net loss per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted was $5.11 for the year ended September 30, 2026.
  • Total cash resources (Cash, cash equivalents and restricted cash and Available-for-sale securities, at fair value) were $1,192,983 thousand as of September 30, 2026.

Guidance

  • The Company is preparing for a potential U.S. launch of plozasiran in sHTG in the second quarter of 2027.
  • The Company anticipates that the YOSEMITE clinical trial will be completed in mid-2027.

Notes

On November 9, 2026, the Board of Directors approved a change in the Company’s fiscal year end from September 30 to December 31, effective as of January 1, 2027.

Price and volatility reaction

The stock moved +1.3% on the print. No front-expiry chain was on file, so there is no straddle expected move.

MeasureValueBasis
Close before release47.152026-11-12
Close after release47.782026-11-13
Realised move+1.3%close to close
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →